Ключевые слова:
кишечная микробиота, метаболический синдром, хроническая болезнь почек, ось «кишечник-почка», уремические токсины, триметиламин-N-оксид, короткоцепочечные жирные кислоты, пробиотики.Библиографические ссылки
1. Thomas G, Sehgal AR, Kashyap SR, Srinivas TR, Kirwan JP, Navaneethan SD. Metabolic syndrome and kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol. 2011;6(10):2364-2373. DOI:10.2215/CJN.02180311.
2. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature. 2006;444(7122):1027-1031. DOI: 10.1038/nature05414.
3. Qin J, Li Y, Cai Z, Li S, Zhu J, Zhang F, et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature. 2012;490(7418):55-60. DOI:10.1038/nature11450.
4. Vaziri ND, Wong J, Pahl M, Piceno YM, Yuan J, DeSantis TZ, et al. Chronic kidney disease alters intestinal microbial flora. Kidney Int. 2013;83(2):308-315. DOI:10.1038/ki.2012.345.
5. Wong J, Piceno YM, DeSantis TZ, Pahl M, Andersen GL, Vaziri ND. Expansion of urease- and uricase-containing, indole- and p-cresol-forming and contraction of short-chain fatty acid-producing intestinal microbiota in ESRD. Am J Nephrol. 2014;39 (3):230-237. DOI:10.1159/000360010.
6. Koh A, De Vadder F, Kovatcheva-Datchary P, Bäckhed F. From dietary fiber to host physiology: short-chain fatty acids as key bacterial metabolites. Cell. 2016;165(6):1332-1345. DOI: 10.1016/j.cell.20 16.05.041.
7. Ramezani A, Raj DS. The gut microbiome, kidney disease, and targeted interventions. J Am Soc Nephrol. 2014;25(4):657-670. DOI:10.1681/ASN.20 13080905.
8. Everard A, Belzer C, Geurts L, Ouwerkerk JP, Druart C, Bindels LB, et al. Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. Proc Natl Acad Sci U S A. 2013;110(22):9066-9071. DOI:10.1073/pnas.121 9451110.
9. Depommier C, Everard A, Druart C, Plovier H, Van Hul M, Vieira-Silva S, et al. Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study. Nat Med. 2019;25(7):1096-1103. DOI: 10.1038/s41591-019-0495-2.
10. Vrieze A, Van Nood E, Holleman F, Salojärvi J, Kootte RS, Bartelsman JF, et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology. 2012;143(4):913-916.e7. DOI: 10. 1053/j.gastro.2012.06.031.
11. Kootte RS, Levin E, Salojärvi J, Smits LP, Hartstra AV, Udayappan SD, et al. Improvement of insulin sensitivity after lean donor feces in metabolic syndrome is driven by baseline intestinal microbiota composition. Cell Metab. 2017;26(4):611-619.e6. DOI: 10.1016/j.cmet.2017.09.008.
12. Cani PD, Amar J, Iglesias MA, Poggi M, Knauf C, Bastelica D, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes. 2007;56(7):1761-1772. DOI:10.2337/db06-1491.
13. Andrade-Oliveira V, Amano MT, Correa-Costa M, Castoldi A, Felizardo RJ, de Almeida DC, et al. Gut bacteria products prevent AKI induced by ischemia-reperfusion. J Am Soc Nephrol. 2015;26(8): 1877-1888. DOI:10.1681/ASN.2014030288.
14. Li YJ, Chen X, Kwan TK, Loh YW, Singer J, Liu Y, et al. Dietary fiber protects against diabetic nephropathy through short-chain fatty acid-mediated activation of G protein-coupled receptors GPR43 and GPR109A. J Am Soc Nephrol. 2020;31(6): 1267-1281. DOI:10.1681/ASN.2019101029.
15. Atzeni A, Díaz-López A, Hernández Cacho A, Bulló M, Babio N, Salas-Salvadó J, et al. Gut microbiota dynamics and association with chronic kidney disease: a longitudinal study within the PREDIMED-Plus trial. Life Sci. 2024;351:122863. DOI: 10.1016/ j.lfs.2024.122863.
16. Vanholder R, Schepers E, Pletinck A, Nagler EV, Glorieux G. The uremic toxicity of indoxyl sulfate and p-cresyl sulfate: a systematic review. J Am Soc Nephrol. 2014;25(9):1897-1907. DOI:10.1681/ASN. 2013101062.
17. Wang Z, Klipfell E, Bennett BJ, Koeth R, Levison BS, Dugar B, et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature. 2011;472(7341):57-63. DOI:10.1038/ nature09922.
18. Tang WH, Wang Z, Kennedy DJ, Wu Y, Buffa JA, Agatisa-Boyle B, et al. Gut microbiota-dependent trimethylamine N-oxide (TMAO) pathway contributes to both development of renal insufficiency and mortality risk in chronic kidney disease. Circ Res. 2015;116(3):448-455. DOI:10.1161/CIRCRESAHA.1 16.305360.
19. Missailidis C, Hällqvist J, Qureshi AR, Barany P, Heimbürger O, Lindholm B, et al. Serum trimethylamine-N-oxide is strongly related to renal function and predicts outcome in chronic kidney disease. PLoS One. 2016;11(1):e0141738. DOI: 10.1371 /journal.pone.0141738.
20. Zhou Z, Jin H, Ju H, Sun M, Chen H, Li L. Circulating trimethylamine-N-oxide and risk of all-cause and cardiovascular mortality in patients with chronic kidney disease: a systematic review and meta-analysis. Front Med (Lausanne). 2022; 9:82 8343. DOI:10.3389/fmed.2022.828343.
21. Pluznick JL, Protzko RJ, Gevorgyan H, Peterlin Z, Sipos A, Han J, et al. Olfactory receptor responding to gut microbiota-derived signals plays a role in renin secretion and blood pressure regulation. Proc Natl Acad Sci U S A. 2013;110(11):4410-4415. DOI:10.1073/pnas.1215927110.
22. O'Donnell JA, Zheng T, Meric G, Marques FZ. The gut microbiome and hypertension. Nat Rev Nephrol. 2023;19(3):153-167. DOI:10.1038/s4158 1-022-00654-0.
23. Tan J, Zhou H, Deng J, Sun J, Zhou X, Tang Y, et al. Effectiveness of microecological preparations for improving renal function and metabolic profiles in patients with chronic kidney disease. Front Nutr. 2022;9:850014. DOI:10.3389/fnut.2022.850014.
24. Sun S, Yu Z, Zhao J, Qin Y, Wang Y, Zhang Y. Probiotics, prebiotics, and synbiotics improve uremic, inflammatory, and gastrointestinal symptoms in end-stage renal disease with dialysis: a network meta-analysis of randomized controlled trials. Front Nutr. 2022; 9:850425. DOI:10.3389/fnut.2022.8504 25.
25. Yuan X, Liu C, Wang J, Lei L, Li L. Gut microbiota therapy for chronic kidney disease. Front Immunol. 2025; 16:1660226. DOI:10.3389/fimmu.202 5.1660226.